Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Relicpixant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Relicpixant: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Suvecaltamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Suvecaltamide: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PfSPZ-LARC2 Vaccine(Sanaria) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
PfSPZ-LARC2 Vaccine(Sanaria): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key r
9 min read
Recombinant human anti-rabies virus monoclonal antibody (Lanzhou Institute of Biological Products) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Recombinant human anti-rabies virus monoclonal antibody (Lanzhou Institute of Biological Products): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals,
9 min read
NRP-2945 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NRP-2945: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Ontunisertib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Ontunisertib: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BVAC-C Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
BVAC-C: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Acmopatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Acmopatide: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Uprosertib/Trametinib Dimethyl Sulfoxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Uprosertib/Trametinib Dimethyl Sulfoxide: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market positio
9 min read
Trosunilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Trosunilimab: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
VRC-MARADC087-00-VP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
VRC-MARADC087-00-VP: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.